Share Price and Basic Stock Data
Last Updated: April 25, 2025, 10:25 pm
| PEG Ratio | 0.00 |
|---|
Competitors of Brooks Laboratories Ltd
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Lactose (India) Ltd | 171 Cr. | 121 | 247/84.3 | 24.7 | 36.5 | 0.00 % | 18.0 % | 15.5 % | 10.0 |
| MPS Pharmaa Ltd | 5.44 Cr. | 2.85 | 4.33/2.75 | 0.80 | 0.00 % | 9.15 % | 34.9 % | 10.0 | |
| Gujarat Themis Biosyn Ltd | 2,663 Cr. | 244 | 390/192 | 50.6 | 20.5 | 0.27 % | 45.0 % | 33.8 % | 1.00 |
| Gujarat Terce Laboratories Ltd | 46.3 Cr. | 62.4 | 94.9/44.5 | 15.7 | 11.9 | 0.00 % | 9.72 % | 3.44 % | 10.0 |
| Gujarat Inject (Kerala) Ltd | 29.3 Cr. | 20.0 | 29.0/13.1 | 29.9 | 6.64 | 0.00 % | 2.65 % | 2.08 % | 10.0 |
| Industry Average | 17,950.21 Cr | 1,096.77 | 43.69 | 182.18 | 0.38% | 15.90% | 16.66% | 6.30 |
Quarterly Result
| Metric | Dec 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 19.01 | 28.46 | 17.12 | 18.08 | 15.30 | 12.61 | 15.70 | 24.32 | 21.75 | 17.72 | 17.93 | 20.79 | 38.45 |
| Expenses | 25.39 | 32.37 | 25.72 | 27.30 | 23.85 | 16.31 | 19.61 | 25.42 | 25.12 | 27.25 | 19.85 | 24.20 | 41.86 |
| Operating Profit | -6.38 | -3.91 | -8.60 | -9.22 | -8.55 | -3.70 | -3.91 | -1.10 | -3.37 | -9.53 | -1.92 | -3.41 | -3.41 |
| OPM % | -33.56% | -13.74% | -50.23% | -51.00% | -55.88% | -29.34% | -24.90% | -4.52% | -15.49% | -53.78% | -10.71% | -16.40% | -8.87% |
| Other Income | 0.37 | 0.18 | 0.03 | 0.40 | 0.45 | 0.03 | 0.05 | 0.09 | 0.16 | 0.65 | 0.07 | 0.20 | 0.10 |
| Interest | 0.74 | 0.84 | 0.62 | 0.63 | 0.75 | 0.18 | 0.17 | 0.19 | 0.21 | 0.27 | 0.16 | 0.32 | 0.45 |
| Depreciation | 1.88 | 1.95 | 1.98 | 2.28 | 2.33 | 0.44 | 0.44 | 0.44 | 0.43 | 0.46 | 0.40 | 0.43 | 0.78 |
| Profit before tax | -8.63 | -6.52 | -11.17 | -11.73 | -11.18 | -4.29 | -4.47 | -1.64 | -3.85 | -9.61 | -2.41 | -3.96 | -4.54 |
| Tax % | -14.25% | -8.90% | -15.85% | -32.82% | -15.21% | 0.00% | 0.00% | 0.00% | 0.78% | 0.00% | 0.00% | 0.00% | 0.66% |
| Net Profit | -7.40 | -5.93 | -9.40 | -7.87 | -9.48 | -4.29 | -4.47 | -1.64 | -3.88 | -9.61 | -2.41 | -3.96 | -4.57 |
| EPS in Rs | -2.52 | -1.37 | -2.63 | -1.79 | -1.92 | -1.64 | -1.71 | -0.62 | -1.48 | -3.66 | -0.92 | -1.51 | -1.74 |
Last Updated: March 3, 2025, 5:08 pm
Below is a detailed analysis of the quarterly data for Brooks Laboratories Ltd based on the most recent figures (Dec 2024) and their trends compared to the previous period:
- For Sales, as of Dec 2024, the value is 38.45 Cr.. The value appears strong and on an upward trend. It has increased from 20.79 Cr. (Sep 2024) to 38.45 Cr., marking an increase of 17.66 Cr..
- For Expenses, as of Dec 2024, the value is 41.86 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 24.20 Cr. (Sep 2024) to 41.86 Cr., marking an increase of 17.66 Cr..
- For Operating Profit, as of Dec 2024, the value is -3.41 Cr.. The value remains steady. There is no change compared to the previous period (Sep 2024) which recorded -3.41 Cr..
- For OPM %, as of Dec 2024, the value is -8.87%. The value appears strong and on an upward trend. It has increased from -16.40% (Sep 2024) to -8.87%, marking an increase of 7.53%.
- For Other Income, as of Dec 2024, the value is 0.10 Cr.. The value appears to be declining and may need further review. It has decreased from 0.20 Cr. (Sep 2024) to 0.10 Cr., marking a decrease of 0.10 Cr..
- For Interest, as of Dec 2024, the value is 0.45 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 0.32 Cr. (Sep 2024) to 0.45 Cr., marking an increase of 0.13 Cr..
- For Depreciation, as of Dec 2024, the value is 0.78 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 0.43 Cr. (Sep 2024) to 0.78 Cr., marking an increase of 0.35 Cr..
- For Profit before tax, as of Dec 2024, the value is -4.54 Cr.. The value appears to be declining and may need further review. It has decreased from -3.96 Cr. (Sep 2024) to -4.54 Cr., marking a decrease of 0.58 Cr..
- For Tax %, as of Dec 2024, the value is 0.66%. The value appears to be increasing, which may not be favorable. It has increased from 0.00% (Sep 2024) to 0.66%, marking an increase of 0.66%.
- For Net Profit, as of Dec 2024, the value is -4.57 Cr.. The value appears to be declining and may need further review. It has decreased from -3.96 Cr. (Sep 2024) to -4.57 Cr., marking a decrease of 0.61 Cr..
- For EPS in Rs, as of Dec 2024, the value is -1.74. The value appears to be declining and may need further review. It has decreased from -1.51 (Sep 2024) to -1.74, marking a decrease of 0.23.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: March 6, 2025, 4:39 pm
| Metric | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | TTM |
|---|---|---|---|---|---|
| Sales | 77 | 91 | 63 | 79 | 95 |
| Expenses | 77 | 105 | 93 | 97 | 113 |
| Operating Profit | 1 | -14 | -30 | -18 | -18 |
| OPM % | 1% | -16% | -47% | -23% | -19% |
| Other Income | 1 | 1 | 1 | 1 | 1 |
| Interest | 3 | 3 | 2 | 1 | 1 |
| Depreciation | 7 | 7 | 7 | 2 | 2 |
| Profit before tax | -9 | -24 | -38 | -20 | -21 |
| Tax % | 115% | -19% | -19% | 0% | |
| Net Profit | -19 | -19 | -31 | -20 | -21 |
| EPS in Rs | -7.40 | -4.31 | -7.97 | -7.46 | -7.83 |
| Dividend Payout % | 0% | 0% | 0% | 0% |
YoY Net Profit Growth
| Year | 2021-2022 | 2022-2023 | 2023-2024 |
|---|---|---|---|
| YoY Net Profit Growth (%) | 0.00% | -63.16% | 35.48% |
| Change in YoY Net Profit Growth (%) | 0.00% | -63.16% | 98.64% |
Brooks Laboratories Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 3 years from 2021-2022 to 2023-2024.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 1% |
| TTM: | 28% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 0% |
| TTM: | -44% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 13% |
| 5 Years: | 32% |
| 3 Years: | 15% |
| 1 Year: | 29% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | -22% |
| Last Year: | -28% |
Last Updated: Unknown
Balance Sheet
Last Updated: November 15, 2024, 1:33 am
| Month | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Sep 2024 |
|---|---|---|---|---|---|
| Equity Capital | 25 | 25 | 25 | 26 | 26 |
| Reserves | 54 | 63 | 49 | 39 | 33 |
| Borrowings | 31 | 25 | 7 | 6 | 9 |
| Other Liabilities | 52 | 83 | 29 | 19 | 23 |
| Total Liabilities | 162 | 196 | 110 | 90 | 91 |
| Fixed Assets | 108 | 110 | 15 | 14 | 15 |
| CWIP | 1 | 15 | 0 | 0 | 0 |
| Investments | 0 | 0 | 64 | 43 | 36 |
| Other Assets | 54 | 71 | 31 | 34 | 41 |
| Total Assets | 162 | 196 | 110 | 90 | 91 |
Below is a detailed analysis of the balance sheet data for Brooks Laboratories Ltd based on the most recent figures (Sep 2024) and their trends compared to the previous period:
- For Equity Capital, as of Sep 2024, the value is ₹26.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 26.00 Cr..
- For Reserves, as of Sep 2024, the value is ₹33.00 Cr.. The value appears to be declining and may need further review. It has decreased from 39.00 Cr. (Mar 2024) to ₹33.00 Cr., marking a decrease of 6.00 Cr..
- For Borrowings, as of Sep 2024, the value is ₹9.00 Cr.. The value appears to be increasing, which may not be favorable. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has increased from 6.00 Cr. (Mar 2024) to ₹9.00 Cr., marking an increase of 3.00 Cr..
- For Other Liabilities, as of Sep 2024, the value is ₹23.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 19.00 Cr. (Mar 2024) to ₹23.00 Cr., marking an increase of 4.00 Cr..
- For Total Liabilities, as of Sep 2024, the value is ₹91.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 90.00 Cr. (Mar 2024) to ₹91.00 Cr., marking an increase of 1.00 Cr..
- For Fixed Assets, as of Sep 2024, the value is ₹15.00 Cr.. The value appears strong and on an upward trend. It has increased from 14.00 Cr. (Mar 2024) to ₹15.00 Cr., marking an increase of 1.00 Cr..
- For CWIP, as of Sep 2024, the value is ₹0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 0.00 Cr..
- For Investments, as of Sep 2024, the value is ₹36.00 Cr.. The value appears to be declining and may need further review. It has decreased from 43.00 Cr. (Mar 2024) to ₹36.00 Cr., marking a decrease of 7.00 Cr..
- For Other Assets, as of Sep 2024, the value is ₹41.00 Cr.. The value appears strong and on an upward trend. It has increased from 34.00 Cr. (Mar 2024) to ₹41.00 Cr., marking an increase of 7.00 Cr..
- For Total Assets, as of Sep 2024, the value is ₹91.00 Cr.. The value appears strong and on an upward trend. It has increased from 90.00 Cr. (Mar 2024) to ₹91.00 Cr., marking an increase of 1.00 Cr..
Notably, the Reserves (33.00 Cr.) exceed the Borrowings (9.00 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow
| Month | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 |
|---|---|---|---|---|
Free Cash Flow
| Month | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 |
|---|---|---|---|---|
| Free Cash Flow | -30.00 | -39.00 | -37.00 | -24.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 |
|---|---|---|---|---|
| Debtor Days | 65 | 71 | 74 | 75 |
| Inventory Days | 178 | 157 | 80 | 60 |
| Days Payable | 233 | 159 | 165 | 97 |
| Cash Conversion Cycle | 9 | 68 | -12 | 38 |
| Working Capital Days | -5 | 95 | -3 | 58 |
| ROCE % | -16% | -30% | -25% |
Mutual Fund Holdings
| Fund Name | No of Shares | AUM (%) | Amount Invested (Cr) | Previous Number of Shares | Previous Date | Percentage Change |
|---|---|---|---|---|---|---|
| Quant Business Cycle Fund | 528,937 | 0.84 | 6.69 | 528,937 | 2025-04-22 17:25:39 | 0% |
| Quant Healthcare Fund | 276,708 | 1.99 | 3.5 | 276,708 | 2025-04-22 17:25:39 | 0% |
| Quant Small Cap Fund | 187,346 | 0.02 | 2.37 | 187,346 | 2025-04-22 17:25:39 | 0% |
Key Financial Ratios
| Month | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|
| FaceValue | 10.00 | 10.00 | 10.00 | 10.00 |
| Basic EPS (Rs.) | -7.65 | -12.57 | -7.82 | -7.84 |
| Diluted EPS (Rs.) | -7.65 | -12.57 | -7.82 | -7.84 |
| Cash EPS (Rs.) | 1.26 | -8.39 | -4.84 | -4.95 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 24.99 | 29.94 | 54.37 | 32.04 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 24.99 | 29.94 | 54.37 | 32.04 |
| Revenue From Operations / Share (Rs.) | 30.28 | 25.59 | 36.87 | 31.27 |
| PBDIT / Share (Rs.) | 1.59 | -10.61 | -5.44 | 0.50 |
| PBIT / Share (Rs.) | 0.91 | -13.46 | -8.42 | -2.38 |
| PBT / Share (Rs.) | 0.59 | -14.20 | -9.67 | -3.64 |
| Net Profit / Share (Rs.) | 0.58 | -11.23 | -7.82 | -7.84 |
| NP After MI And SOA / Share (Rs.) | -7.46 | -8.46 | -6.55 | -7.84 |
| PBDIT Margin (%) | 5.24 | -41.47 | -14.76 | 1.62 |
| PBIT Margin (%) | 3.01 | -52.59 | -22.83 | -7.62 |
| PBT Margin (%) | 1.95 | -55.48 | -26.23 | -11.63 |
| Net Profit Margin (%) | 1.92 | -43.89 | -21.20 | -25.07 |
| NP After MI And SOA Margin (%) | -24.64 | -33.06 | -17.77 | -25.08 |
| Return on Networth / Equity (%) | -29.87 | -28.26 | -25.67 | -24.47 |
| Return on Capital Employeed (%) | 3.56 | -43.41 | -14.14 | -5.98 |
| Return On Assets (%) | -21.66 | -19.06 | -8.26 | -11.95 |
| Long Term Debt / Equity (X) | 0.00 | 0.00 | 0.14 | 0.18 |
| Total Debt / Equity (X) | 0.07 | 0.07 | 0.38 | 0.35 |
| Asset Turnover Ratio (%) | 0.79 | 0.41 | 0.57 | 0.00 |
| Current Ratio (X) | 1.35 | 0.83 | 1.25 | 0.78 |
| Quick Ratio (X) | 0.93 | 0.49 | 0.68 | 0.41 |
| Inventory Turnover Ratio (X) | 4.28 | 2.14 | 2.31 | 0.00 |
| Interest Coverage Ratio (X) | 4.94 | -12.01 | -4.34 | 0.40 |
| Interest Coverage Ratio (Post Tax) (X) | 2.81 | -11.87 | -5.24 | -5.25 |
| Enterprise Value (Cr.) | 247.92 | 159.23 | 271.01 | 179.90 |
| EV / Net Operating Revenue (X) | 3.12 | 2.52 | 2.98 | 2.33 |
| EV / EBITDA (X) | 59.41 | -6.07 | -20.15 | 143.19 |
| MarketCap / Net Operating Revenue (X) | 3.06 | 2.45 | 1.97 | 1.99 |
| Price / BV (X) | 3.71 | 2.09 | 2.84 | 1.94 |
| Price / Net Operating Revenue (X) | 3.06 | 2.45 | 1.97 | 1.99 |
| EarningsYield | -0.08 | -0.13 | -0.09 | -0.12 |
After reviewing the key financial ratios for Brooks Laboratories Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 24, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 23) which recorded 10.00.
- For Basic EPS (Rs.), as of Mar 24, the value is -7.65. This value is below the healthy minimum of 5. It has increased from -12.57 (Mar 23) to -7.65, marking an increase of 4.92.
- For Diluted EPS (Rs.), as of Mar 24, the value is -7.65. This value is below the healthy minimum of 5. It has increased from -12.57 (Mar 23) to -7.65, marking an increase of 4.92.
- For Cash EPS (Rs.), as of Mar 24, the value is 1.26. This value is below the healthy minimum of 3. It has increased from -8.39 (Mar 23) to 1.26, marking an increase of 9.65.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 24, the value is 24.99. It has decreased from 29.94 (Mar 23) to 24.99, marking a decrease of 4.95.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 24, the value is 24.99. It has decreased from 29.94 (Mar 23) to 24.99, marking a decrease of 4.95.
- For Revenue From Operations / Share (Rs.), as of Mar 24, the value is 30.28. It has increased from 25.59 (Mar 23) to 30.28, marking an increase of 4.69.
- For PBDIT / Share (Rs.), as of Mar 24, the value is 1.59. This value is below the healthy minimum of 2. It has increased from -10.61 (Mar 23) to 1.59, marking an increase of 12.20.
- For PBIT / Share (Rs.), as of Mar 24, the value is 0.91. This value is within the healthy range. It has increased from -13.46 (Mar 23) to 0.91, marking an increase of 14.37.
- For PBT / Share (Rs.), as of Mar 24, the value is 0.59. This value is within the healthy range. It has increased from -14.20 (Mar 23) to 0.59, marking an increase of 14.79.
- For Net Profit / Share (Rs.), as of Mar 24, the value is 0.58. This value is below the healthy minimum of 2. It has increased from -11.23 (Mar 23) to 0.58, marking an increase of 11.81.
- For NP After MI And SOA / Share (Rs.), as of Mar 24, the value is -7.46. This value is below the healthy minimum of 2. It has increased from -8.46 (Mar 23) to -7.46, marking an increase of 1.00.
- For PBDIT Margin (%), as of Mar 24, the value is 5.24. This value is below the healthy minimum of 10. It has increased from -41.47 (Mar 23) to 5.24, marking an increase of 46.71.
- For PBIT Margin (%), as of Mar 24, the value is 3.01. This value is below the healthy minimum of 10. It has increased from -52.59 (Mar 23) to 3.01, marking an increase of 55.60.
- For PBT Margin (%), as of Mar 24, the value is 1.95. This value is below the healthy minimum of 10. It has increased from -55.48 (Mar 23) to 1.95, marking an increase of 57.43.
- For Net Profit Margin (%), as of Mar 24, the value is 1.92. This value is below the healthy minimum of 5. It has increased from -43.89 (Mar 23) to 1.92, marking an increase of 45.81.
- For NP After MI And SOA Margin (%), as of Mar 24, the value is -24.64. This value is below the healthy minimum of 8. It has increased from -33.06 (Mar 23) to -24.64, marking an increase of 8.42.
- For Return on Networth / Equity (%), as of Mar 24, the value is -29.87. This value is below the healthy minimum of 15. It has decreased from -28.26 (Mar 23) to -29.87, marking a decrease of 1.61.
- For Return on Capital Employeed (%), as of Mar 24, the value is 3.56. This value is below the healthy minimum of 10. It has increased from -43.41 (Mar 23) to 3.56, marking an increase of 46.97.
- For Return On Assets (%), as of Mar 24, the value is -21.66. This value is below the healthy minimum of 5. It has decreased from -19.06 (Mar 23) to -21.66, marking a decrease of 2.60.
- For Long Term Debt / Equity (X), as of Mar 24, the value is 0.00. This value is below the healthy minimum of 0.2. There is no change compared to the previous period (Mar 23) which recorded 0.00.
- For Total Debt / Equity (X), as of Mar 24, the value is 0.07. This value is within the healthy range. There is no change compared to the previous period (Mar 23) which recorded 0.07.
- For Asset Turnover Ratio (%), as of Mar 24, the value is 0.79. It has increased from 0.41 (Mar 23) to 0.79, marking an increase of 0.38.
- For Current Ratio (X), as of Mar 24, the value is 1.35. This value is below the healthy minimum of 1.5. It has increased from 0.83 (Mar 23) to 1.35, marking an increase of 0.52.
- For Quick Ratio (X), as of Mar 24, the value is 0.93. This value is below the healthy minimum of 1. It has increased from 0.49 (Mar 23) to 0.93, marking an increase of 0.44.
- For Inventory Turnover Ratio (X), as of Mar 24, the value is 4.28. This value is within the healthy range. It has increased from 2.14 (Mar 23) to 4.28, marking an increase of 2.14.
- For Interest Coverage Ratio (X), as of Mar 24, the value is 4.94. This value is within the healthy range. It has increased from -12.01 (Mar 23) to 4.94, marking an increase of 16.95.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 24, the value is 2.81. This value is below the healthy minimum of 3. It has increased from -11.87 (Mar 23) to 2.81, marking an increase of 14.68.
- For Enterprise Value (Cr.), as of Mar 24, the value is 247.92. It has increased from 159.23 (Mar 23) to 247.92, marking an increase of 88.69.
- For EV / Net Operating Revenue (X), as of Mar 24, the value is 3.12. This value exceeds the healthy maximum of 3. It has increased from 2.52 (Mar 23) to 3.12, marking an increase of 0.60.
- For EV / EBITDA (X), as of Mar 24, the value is 59.41. This value exceeds the healthy maximum of 15. It has increased from -6.07 (Mar 23) to 59.41, marking an increase of 65.48.
- For MarketCap / Net Operating Revenue (X), as of Mar 24, the value is 3.06. This value exceeds the healthy maximum of 3. It has increased from 2.45 (Mar 23) to 3.06, marking an increase of 0.61.
- For Price / BV (X), as of Mar 24, the value is 3.71. This value exceeds the healthy maximum of 3. It has increased from 2.09 (Mar 23) to 3.71, marking an increase of 1.62.
- For Price / Net Operating Revenue (X), as of Mar 24, the value is 3.06. This value exceeds the healthy maximum of 3. It has increased from 2.45 (Mar 23) to 3.06, marking an increase of 0.61.
- For EarningsYield, as of Mar 24, the value is -0.08. This value is below the healthy minimum of 5. It has increased from -0.13 (Mar 23) to -0.08, marking an increase of 0.05.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Brooks Laboratories Ltd:
- Net Profit Margin: 1.92%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 3.56% (Industry Average ROCE: 15.9%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: -29.87% (Industry Average ROE: 16.66%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 2.81
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 0.93
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 0 (Industry average Stock P/E: 43.69)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.07
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 1.92%
About the Company - Qualitative Analysis
Brooks Laboratories Ltd. is a Public Limited Listed company incorporated on 23/01/2002 and has its registered office in the State of Himachal Pradesh, India. Company's Corporate Identification Number(CIN) is L24232HP2002PLC000267 and registration number is 000267. Currently Company is involved in the business activities of Manufacture of pharmaceuticals, medicinal chemical and botanical products. Company's Total Operating Revenue is Rs. 79.49 Cr. and Equity Capital is Rs. 26.25 Cr. for the Year ended 31/03/2024.
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Pharmaceuticals | Unit 1: Village Kishanpura,. Solan District Himachal Pradesh 174101 | investors@brookslabs.net http://www.brookslabs.net |
| Management | |
|---|---|
| Name | Position Held |
| Ms. Sonia Gupta | Independent Director |
| Mr. Jitendra Pratap Singh | Whole Time Director |
| Mr. Durga Shankar Maity | Whole Time Director |
| Mr. Bhushan Singh Rana | Whole Time Director |
| Mr. Lalit Mahajan | Addnl.Independent Director |
| Dr. Usha Singh | Addnl.Independent Director |
FAQ
What is the intrinsic value of Brooks Laboratories Ltd?
Brooks Laboratories Ltd's intrinsic value (as of 28 April 2025) is ₹77.73 — 44.48% lower the current market price of 140.00, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's 412 Cr. market cap, FY2025-2026 high/low of ₹203/72.5, reserves of 33 Cr, and liabilities of 91 Cr.
What is the Market Cap of Brooks Laboratories Ltd?
The Market Cap of Brooks Laboratories Ltd is 412 Cr..
What is the current Stock Price of Brooks Laboratories Ltd as on 28 April 2025?
The current stock price of Brooks Laboratories Ltd as on 28 April 2025 is 140.
What is the High / Low of Brooks Laboratories Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Brooks Laboratories Ltd stocks is ₹203/72.5.
What is the Stock P/E of Brooks Laboratories Ltd?
The Stock P/E of Brooks Laboratories Ltd is .
What is the Book Value of Brooks Laboratories Ltd?
The Book Value of Brooks Laboratories Ltd is 22.6.
What is the Dividend Yield of Brooks Laboratories Ltd?
The Dividend Yield of Brooks Laboratories Ltd is 0.00 %.
What is the ROCE of Brooks Laboratories Ltd?
The ROCE of Brooks Laboratories Ltd is 24.7 %.
What is the ROE of Brooks Laboratories Ltd?
The ROE of Brooks Laboratories Ltd is 28.1 %.
What is the Face Value of Brooks Laboratories Ltd?
The Face Value of Brooks Laboratories Ltd is 10.0.